Eisai Limited

Clinical research includes early Alzheimer’s disease, mild cognitive impairment due to Alzheimer’s disease, mild Alzheimer’s disease dementia, and preclinical Alzheimer’s disease with elevated or intermediate amyloid. The portfolio also includes work in cognitive decline and long-term assessment of memory and functional change.

• Preclinical Alzheimer’s disease
• Early Alzheimer’s disease
• Intermediate amyloid and elevated amyloid
• Mild cognitive impairment

These studies focus on disease stages before and after clinical symptom onset, with interest in markers of brain amyloid burden and cognitive performance.